443 related articles for article (PubMed ID: 32029870)
21. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Couch FJ; Hart SN; Sharma P; Toland AE; Wang X; Miron P; Olson JE; Godwin AK; Pankratz VS; Olswold C; Slettedahl S; Hallberg E; Guidugli L; Davila JI; Beckmann MW; Janni W; Rack B; Ekici AB; Slamon DJ; Konstantopoulou I; Fostira F; Vratimos A; Fountzilas G; Pelttari LM; Tapper WJ; Durcan L; Cross SS; Pilarski R; Shapiro CL; Klemp J; Yao S; Garber J; Cox A; Brauch H; Ambrosone C; Nevanlinna H; Yannoukakos D; Slager SL; Vachon CM; Eccles DM; Fasching PA
J Clin Oncol; 2015 Feb; 33(4):304-11. PubMed ID: 25452441
[TBL] [Abstract][Full Text] [Related]
22. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
[TBL] [Abstract][Full Text] [Related]
23. Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing.
Shimelis H; LaDuca H; Hu C; Hart SN; Na J; Thomas A; Akinhanmi M; Moore RM; Brauch H; Cox A; Eccles DM; Ewart-Toland A; Fasching PA; Fostira F; Garber J; Godwin AK; Konstantopoulou I; Nevanlinna H; Sharma P; Yannoukakos D; Yao S; Feng BJ; Tippin Davis B; Lilyquist J; Pesaran T; Goldgar DE; Polley EC; Dolinsky JS; Couch FJ
J Natl Cancer Inst; 2018 Aug; 110(8):855-862. PubMed ID: 30099541
[TBL] [Abstract][Full Text] [Related]
24. Germline Mutation in 1338 BRCA-Negative Chinese Hereditary Breast and/or Ovarian Cancer Patients: Clinical Testing with a Multigene Test Panel.
Kwong A; Shin VY; Chen J; Cheuk IWY; Ho CYS; Au CH; Chan KKL; Ngan HYS; Chan TL; Ford JM; Ma ESK
J Mol Diagn; 2020 Apr; 22(4):544-554. PubMed ID: 32068069
[TBL] [Abstract][Full Text] [Related]
25. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
[TBL] [Abstract][Full Text] [Related]
27. Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria.
Hoyer J; Vasileiou G; Uebe S; Wunderle M; Kraus C; Fasching PA; Thiel CT; Hartmann A; Beckmann MW; Lux MP; Reis A
BMC Cancer; 2018 Sep; 18(1):926. PubMed ID: 30257646
[TBL] [Abstract][Full Text] [Related]
28. Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers.
Nones K; Johnson J; Newell F; Patch AM; Thorne H; Kazakoff SH; de Luca XM; Parsons MT; Ferguson K; Reid LE; McCart Reed AE; Srihari S; Lakis V; Davidson AL; Mukhopadhyay P; Holmes O; Xu Q; Wood S; Leonard C; ; ; ; Beesley J; Harris JM; Barnes D; Degasperi A; Ragan MA; Spurdle AB; Khanna KK; Lakhani SR; Pearson JV; Nik-Zainal S; Chenevix-Trench G; Waddell N; Simpson PT
Ann Oncol; 2019 Jul; 30(7):1071-1079. PubMed ID: 31090900
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
31. Germline pathogenic variants in BRCA1, BRCA2, PALB2 and RAD51C in breast cancer women from Argentina.
Cerretini R; Mercado G; Morganstein J; Schiaffi J; Reynoso M; Montoya D; Valdéz R; Narod SA; Akbari MR
Breast Cancer Res Treat; 2019 Dec; 178(3):629-636. PubMed ID: 31446535
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and oncologic outcomes of BRCA 1/2 mutations in unselected triple-negative breast cancer patients in Korea.
Ryu JM; Choi HJ; Kim I; Nam SJ; Kim SW; Yu J; Lee SK; Choi DH; Park YH; Kim JW; Seo JS; Park JH; Lee JE; Kim SW;
Breast Cancer Res Treat; 2019 Jan; 173(2):385-395. PubMed ID: 30350268
[TBL] [Abstract][Full Text] [Related]
33. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
34. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
35. Mutations of
Tsyganov MM; Sorokovikova SS; Lutzkaya EA; Ibragimova MK
Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628606
[TBL] [Abstract][Full Text] [Related]
36. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of pathogenetic mutations in breast cancer predisposition genes in population-based studies conducted among Chinese women.
Zeng C; Guo X; Wen W; Shi J; Long J; Cai Q; Shu XO; Xiang Y; Zheng W
Breast Cancer Res Treat; 2020 Jun; 181(2):465-473. PubMed ID: 32318955
[TBL] [Abstract][Full Text] [Related]
38. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
[TBL] [Abstract][Full Text] [Related]
39. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
[TBL] [Abstract][Full Text] [Related]
40. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer.
Kapoor NS; Curcio LD; Blakemore CA; Bremner AK; McFarland RE; West JG; Banks KC
Ann Surg Oncol; 2015 Oct; 22(10):3282-8. PubMed ID: 26219241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
